Our primary focus will be on the life sciences industry, which we believe represents a growing target market with a large number of potential target acquisition opportunities. With more than 5,000 diseases in need of effective treatment, and approximately 150 novel chemical entities approved in 2020 of which 97 were approved by the European Medicines Agency and 53 by the United States Food and Drug Administration, we believe that demand for new therapies from the global healthcare industry remains high. Continued high global demand is also driven by demographic developments, such as an aging population and improving health standards worldwide. As an example, the annual prescription drug market for the United States alone is expected to grow with an annual 4% to $420 billion in 2023. We believe that these trends present a favorable opportunity for investors in clinical-stage companies within the life sciences industry, which is where Forbion has largely focused since inception. (Incorporated in the Cayman Islands)

Founded in 2006, Forbion (“Forbion”) is a life sciences specialist venture fund manager with headquarters in Naarden, the Netherlands, and offices in Munich, Germany, and Singapore. Forbion has established itself as one of the leading brands within the European life sciences industry, supported by a successful track record and strong reputation with co-investors, entrepreneurs, and large pharmaceutical companies (“large pharma”). With 32 employees and a large network of dedicated advisors, Forbion boasts one of the largest teams of specialist investors in Europe, combining investment expertise in private and public markets with hands-on operational expertise in drug development, clinical development, and commercialization. 

(Note: Forbion European Acquisition Corp. upsized its SPAC IPO at pricing on Dec. 9, 2021, to 11 million units, up from 10 million, at $10 each to raise $110 million.)